Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes

References

• Lusis AJ. Atherosclerosis. Nature407(6801), 233–241 (2000).
   PubMed Web of Science ®Google Scholar
• Viljoen A. New approaches in the diagnosis of atherosclerosis and treatment of cardiovascular disease. Recent Pat. Cardiovasc. Drug Discov.3(2), 84–91 (2008).
   Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: the Joint British Societies’ guidelines for prevention of cardiovascular disease in clinical practice. Heart91(Suppl. V), V1–V52 (2005).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil.14(Suppl. 2), S1–S113 (2007).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study Investigators. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol.102(10 Suppl.), 1K–34K (2008).
   Web of Science ®Google Scholar
• Davidson MH. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am. J. Cardiol.96(9A), 3K–13K (2005).
   PubMed Web of Science ®Google Scholar
• Silva MA, Swanson AC, Gandhi PJ et al. Statin-related adverse events: a meta-analysis. Clin. Ther.28(1), 26–35 (2006).
   PubMed Web of Science ®Google Scholar
• Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol.81(4A), 66B–69B (1998).
   PubMed Web of Science ®Google Scholar
• Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler. Thromb. Vasc. Biol.19(2), 187–195 (1999).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Muddy waters: more stormy SEAS for ezetimibe. Int. J. Clin. Pract.62(10), 1470–1473 (2008).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med.358(14), 1431–1443 (2008).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int. J. Clin. Pract.62(7), 981–987 (2008).
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics (LRC) Coronary Primary Prevention Trial Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA251(3), 351–364 (1984).
   PubMed Web of Science ®Google Scholar
• Colesevelam. GT 31104, CholestaGel. Drugs RD1(6), 479–480 (1999).
   PubMedGoogle Scholar
• Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med. J.99(3), 257–273 (2006).
   PubMed Web of Science ®Google Scholar
• Donovan JM, Von BK, Setchell KD et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig. Dis. Sci.50(7), 1232–1238 (2005).
   PubMed Web of Science ®Google Scholar
• Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler. Thromb. Vasc. Biol.25(10), 2020–2030 (2005).
   PubMed Web of Science ®Google Scholar
• Staels B, Fonseca VA. Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care32(Suppl. 2), S237–S245 (2009).
   PubMed Web of Science ®Google Scholar
• Herrema H, Meissner M, van Dijk TH et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor α-controlled metabolic pathways in mice. Hepatology51(3), 806–816 (2010).
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Smisek D et al.In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints41(1), 708–709 (2000).
   Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother.4(5), 779–790 (2003).
   PubMed Web of Science ®Google Scholar
• Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother.35(7–8), 898–907 (2001).
   PubMed Web of Science ®Google Scholar
• Brown DD, Schmid J, Long RA et al. A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J. Clin. Pharmacol.25(5), 360–364 (1985).
   PubMed Web of Science ®Google Scholar
• Donovan JM, Stypinski D, Stiles MR et al. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Ther.14(6), 681–690 (2000).
   PubMed Web of Science ®Google Scholar
• Donovan JM, Kisicki JC, Stiles MR et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann. Pharmacother.36(3), 392–397 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Dillon MA, Gordon B et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med.159(16), 1893–1900 (1999).
   PubMed Web of Science ®Google Scholar
• Insull W Jr, Toth P, Mullican W et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc.76(10), 971–982 (2001).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Toth P, Weiss S et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol.24(6), 467–474 (2001).
   PubMed Web of Science ®Google Scholar
• Hunninghake D, Insull W Jr, Toth P et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis158(2), 407–416 (2001).
   PubMed Web of Science ®Google Scholar
• Knapp HH, Schrott H, Ma P et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med.110(5), 352–360 (2001).
   PubMed Web of Science ®Google Scholar
• Schmidt DR, Holmstrom SR, Fon TK et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem.285(19), 14486–14494 (2010).
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Armani A, McKenney JM et al. Safety considerations with gastrointestinally active lipid-lowering drugs. Am. J. Cardiol.99(6A), 47C–55C (2007).
   PubMed Web of Science ®Google Scholar
• Bays HE, Davidson M, Jones MR et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am. J. Cardiol.97(8), 1198–1205 (2006).
   PubMed Web of Science ®Google Scholar
• Reddy KJ, Singh M, Batsell RR et al. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J. Clin. Hypertens. (Greenwich)11(12), 766–768 (2009).
   Google Scholar
• Xydakis AM, Guyton JR, Chiou P et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am. J. Cardiol.94(6), 795–797 (2004).
   PubMed Web of Science ®Google Scholar
• Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther.12(4), 306–310 (2005).
   PubMedGoogle Scholar
• Knopp RH, Tsunehara C, Retzlaff BM et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism55(12), 1697–1703 (2006).
   PubMed Web of Science ®Google Scholar
• Bays H, Rhyne J, Abby S et al. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr. Med. Res. Opin.22(11), 2191–2200 (2006).
   PubMed Web of Science ®Google Scholar
• Rivers SM, Kane MP, Busch RS et al. Colesevelam hydrochloride–ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr. Pract.13(1), 11–16 (2007).
   PubMedGoogle Scholar
• McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr. Med. Res. Opin.21(9), 1403–1412 (2005).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Autret B, Jialal I. Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am. J. Cardiol.98(5), 641–643 (2006).
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr. Atheroscler. Rep.6(5), 381–387 (2004).
   PubMedGoogle Scholar
• Otvos JD, Collins D, Freedman DS et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation113(12), 1556–1563 (2006).
   PubMed Web of Science ®Google Scholar
• Cromwell WC, Otvos JD, Keyes MJ et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. J. Clin. Lipidol.1(6), 583–592 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis185(2), 327–330 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol.90(2), 89–94 (2002).
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with Type 2 diabetes. Clin. Ther.29(1), 74–83 (2007).
   PubMed Web of Science ®Google Scholar
• Bays HE, Goldberg RB, Truitt KE et al. Colesevelam hydrochloride therapy in patients with Type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med.168(18), 1975–1983 (2008).
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Rosenstock J, Wang AC et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled Type 2 diabetes on sulfonylurea-based therapy. Diabetes Care31(8), 1479–1484 (2008).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Fonseca VA, Truitt KE et al. Efficacy and safety of colesevelam in patients with Type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med.168(14), 1531–1540 (2008).
   PubMed Web of Science ®Google Scholar
• Rigby SP, Handelsman Y, Lai YL et al. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with Type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr. Pract.16(1), 53–63 (2010).
   PubMed Web of Science ®Google Scholar
• Jones MR, Mudaliar S, Hernandez-Triana E et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in Type 2 diabetes and colesevelam HCl in prediabetes. Curr. Med. Res. Opin.25(9), 2239–2249 (2009).
   PubMed Web of Science ®Google Scholar
• Stein EA, Marais AD, Szamosi T et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J. Pediatr.156(2), 231–236 (2010).
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ337, a1095 (2008).
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics (LRC) Coronary Primary Prevention Trial Investigators. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA251(3), 351–364 (1984).
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA231(4), 360–381 (1975).
   PubMed Web of Science ®Google Scholar
• Saha SA, Kizhakepunnur LG, Bahekar A et al. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am. Heart J.154(5), 943–953 (2007).
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet375(9729), 1875–1884 (2010).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med.335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345(22), 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110(23), 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361(22), 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) final results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol.55(24), 2721–2726 (2010).
   PubMed Web of Science ®Google Scholar
• Vogt A, Kassner U, Hostalek U et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr. Med. Res. Opin.22(2), 417–425 (2006).
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials. Lancet375(9716), 735–742 (2010).
   PubMed Web of Science ®Google Scholar
• Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev. Cardiol.6(4), 179–188 (2003).
   PubMedGoogle Scholar
• Guerin M, Lassel TS, Le Goff W et al. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol.20(1), 189–197 (2000).
   PubMed Web of Science ®Google Scholar
• Huijgen R, Abbink EJ, Bruckert E et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin. Ther.32(4), 615–625 (2010).
   PubMed Web of Science ®Google Scholar
• Moore AB, Phan BA, Challender C et al. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J. Clin. Lipidol.1(6), 620–625 (2007).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Steinmetz KL, Schonder KS. Colesevelam: potential uses for the newest bile resin. Cardiovasc. Drug Rev.23(1), 15–30 (2005).
   PubMedGoogle Scholar
• Wedlake L, Thomas K, Lalji A et al. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin. Ther.31(11), 2549–2558 (2009).
   PubMed Web of Science ®Google Scholar
• Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin. Liver Dis.7(4), 879–900 (2003).
   PubMedGoogle Scholar
• Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation114(16), 1729–1735 (2006).
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet375(9719), 998–1006 (2010).
   PubMed Web of Science ®Google Scholar